Barinthus Biotherapeutics (BRNS)

• Market cap: $25.2M
• 1 day: -1.77%
• 5 days: 1.02%
• 1 month: -13.15%
• 3 months: 2.73%
• 6 months: -14.63%
• Year to date: -17.54%
• 1 year: -69.23%
• 5 years: -95.89%
• 10 years: -95.7%
• Sector: Healthcare
• Industry: Biotechnology

About: Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.

Employees: 14